Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate
Matthew T. Villaume,
Eran Sella,
Garrett Saul,
Robert M. Borzilleri,
Joseph Fargnoli,
Kathy A. Johnston,
Haiying Zhang,
Mark P. Fereshteh,
T. G. Murali Dhar,
Phil S. Baran
Affiliations
Matthew T. Villaume
Department of Chemistry, The Scripps Research Institute, La Jolla, California, United States
Eran Sella
Department of Chemistry, The Scripps Research Institute, La Jolla, California, United States
Garrett Saul
Department of Chemistry, The Scripps Research Institute, La Jolla, California, United States
Robert M. Borzilleri
Departments of Discovery Chemistry, Oncology Discovery and Leads Discovery & Optimization, Preclinical Optimization, Bristol-Myers Squibb Co., Princeton, New Jersey, United States
Joseph Fargnoli
Departments of Discovery Chemistry, Oncology Discovery and Leads Discovery & Optimization, Preclinical Optimization, Bristol-Myers Squibb Co., Princeton, New Jersey, United States
Kathy A. Johnston
Departments of Discovery Chemistry, Oncology Discovery and Leads Discovery & Optimization, Preclinical Optimization, Bristol-Myers Squibb Co., Princeton, New Jersey, United States
Haiying Zhang
Departments of Discovery Chemistry, Oncology Discovery and Leads Discovery & Optimization, Preclinical Optimization, Bristol-Myers Squibb Co., Princeton, New Jersey, United States
Mark P. Fereshteh
Departments of Discovery Chemistry, Oncology Discovery and Leads Discovery & Optimization, Preclinical Optimization, Bristol-Myers Squibb Co., Princeton, New Jersey, United States
T. G. Murali Dhar
Departments of Discovery Chemistry, Oncology Discovery and Leads Discovery & Optimization, Preclinical Optimization, Bristol-Myers Squibb Co., Princeton, New Jersey, United States
Phil S. Baran
Department of Chemistry, The Scripps Research Institute, La Jolla, California, United States
